Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer
Open Access
- 9 October 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (1) , 320-329
Abstract
Purpose: The role of immune-oncologic mechanisms of racial disparities in prostate cancer remains understudied. Limited research exists to evaluate the molecular underpinnings of immune differences in African American men (AAM) and European American men (EAM) prostate tumor microenvironment (TME). Experimental Design: A total of 1,173 radiation-naïve radical prostatectomy samples with whole transcriptome data from the Decipher GRID registry were used. Transcriptomic expressions of 1,260 immune-specific genes were selected to assess immune-oncologic differences between AAM and EAM prostate tumors. Race-specific differential expression of genes was assessed using a rank test, and intergene correlational matrix and gene set enrichment was used for pathway analysis. Results: AAM prostate tumors have significant enrichment of major immune-oncologic pathways, including proinflammatory cytokines, IFNα, IFNγ, TNFα signaling, ILs, and epithelial–mesenchymal transition. AAM TME has higher total immune content score (ICSHIGH) compared with 0 (37.8% vs. 21.9%, P = 0.003). AAM tumors also have lower DNA damage repair and are genomically radiosensitive as compared with EAM. IFITM3 (IFN-inducible transmembrane protein 3) was one of the major proinflammatory genes overexpressed in AAM that predicted increased risk of biochemical recurrence selectively for AAM in both discovery [HRAAM = 2.30; 95% confidence interval (CI), 1.21–4.34; P = 0.01] and validation (HRAAM = 2.42; 95% CI, 1.52–3.86; P = 0.0001) but not in EAM. Conclusions: Prostate tumors of AAM manifest a unique immune repertoire and have significant enrichment of proinflammatory immune pathways that are associated with poorer outcomes. Observed immune-oncologic differences can aid in a genomically adaptive approach to treating prostate cancer in AAM.Keywords
All Related Versions
Funding Information
- Prostate Cancer Foundation and Department of Defense (W81XWH-19-1-0435-PC 18103)
This publication has 36 references indexed in Scilit:
- Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk MenEuropean Urology, 2016
- Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate CancerJournal of Clinical Oncology, 2015
- Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor FunctionMolecular Cell, 2015
- Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changesInternational Journal of Cancer, 2013
- A single-sample microarray normalization method to facilitate personalized-medicine workflowsGenomics, 2012
- The CAPRA‐S scoreCancer, 2011
- Molecular signatures database (MSigDB) 3.0Bioinformatics, 2011
- A Gene Expression Model of Intrinsic Tumor Radiosensitivity: Prediction of Response and Prognosis After ChemoradiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American MenCancer Research, 2008
- Apoptosis evasion: The role of survival pathways in prostate cancer progression and therapeutic resistanceJournal of Cellular Biochemistry, 2005